Veradermics announced Monday that VDPHL01, an extended-release oral minoxidil tablet, met all primary and secondary endpoints in Study 304, a Phase 3 trial enrolling 536 men with mild-to-moderate pattern hair loss. The twice-daily arm produced a gain of 36.4 hairs per square centimeter at six months, against 6.6 for placebo. Veradermics calls that the largest improvement ever recorded in a placebo-controlled study for this indication.
The once-daily group came in at 28.6 hairs per square centimeter. Both results reached p<0.0001, and both separated from placebo at month two, the earliest measurement point. No treatment-related serious adverse events and no cardiac adverse events were reported.
This marks Veradermics' second consecutive Phase 3 win. Study 302, reported in April, enrolled 519 men and posted nearly identical figures: 30.3 and 33.0 hairs per square centimeter for the once- and twice-daily arms, respectively, with a similar safety profile. Across both trials, more than 1,000 men have now been dosed. Twelve-month safety data from Study 302 are expected later this year.
The Cardiac Question
Oral minoxidil has been prescribed off-label for hair loss for years, but it remains FDA-approved only as an antihypertensive at doses of 10 to 40 mg per day. At those levels, cardiovascular side effects including fluid retention, tachycardia, and pericardial effusion are well documented. Low-dose oral minoxidil, typically 1 to 5 mg, has emerged as a common workaround, though even at low doses, some studies show dose-dependent increases in heart rate and adverse events.
VDPHL01 is designed to avoid those concerns by spreading minoxidil absorption over a longer window, keeping plasma levels below the threshold where cardiovascular activity begins. According to the company, minoxidil's cardiac effects start at roughly 10 times the blood concentration needed for hair growth.
"Dermatology has been treating hair loss with a drug borrowed from cardiology, in a formulation never intended for our patients, at doses we arrived at informally," said Michael Gold, a dermatologist who served as a trial investigator. He called VDPHL01 the first oral minoxidil formulation developed specifically for pattern hair loss, and the first to generate positive Phase 3 results for both efficacy and safety.
Context and Path Forward
The last oral drug approved for male pattern hair loss was finasteride, which received FDA clearance in December 1997 under the brand name Propecia. Finasteride works by blocking DHT, a hormone implicated in follicle miniaturization, but it carries its own set of side-effect warnings, including persistent sexual dysfunction in a small number of users. VDPHL01, by contrast, has no hormonal mechanism.
Veradermics reported that 68.7 percent of men on the twice-daily dose rated their hair "improved" or "much improved" at six months, compared to 15 percent on placebo. On patient-reported outcome scales, 86 percent of the twice-daily arm reported at least some visible improvement.
Across Studies 302 and 304, five patients discontinued due to peripheral edema. One discontinued due to hypertrichosis, or unwanted hair growth in other areas, a known side effect of oral minoxidil that can lead patients to stop treatment. Trial investigators noted the absence of reported post-treatment shedding, which sometimes causes patients to abandon immediate-release minoxidil early.
Veradermics has not disclosed a submission timeline. The company completed an IPO earlier this year and reported $819.9 million in cash and marketable securities as of June, enough to fund operations into 2030. A Phase 2/3 trial in women, Study 306, is currently enrolling more than 500 participants. Patent protection extends to at least 2043.
Shares of Veradermics rose approximately 10 percent following the announcement, trading around $116 on Monday. Analysts at Cantor Fitzgerald and Leerink Partners said the results exceeded investor benchmarks requiring a 20-plus hair-per-square-centimeter advantage over placebo.
